By webmin on Wed, 01/15/2020 - 22:49 Phone 1-888-771-0141 or 1-908-673-9800 Email N/A ClinicalTrials.gov URL https://clinicaltrials.gov/ct2/results?term=Celgene&Search=Apply&recrs=b&recrs=a&recrs=d&age_v=&gndr=&type=&rslt= Acknowledgement 24 hours EA Page https://www.celgene.com/responsibility/pre-approval-access/ Sponsor Celgene Expanded Access Listings Expanded Access for CC-486 Conditions Acute Myelogenous Leukemia (AML) This is an expanded access program (EAP) for eligible participants designed to provideaccess to CC-486. Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma Conditions Multiple Myeloma To provide pomalidomide access to relapsed/refractory multiple myeloma subjects with alikelihood of benefit from the pomalidomide treatment while the medication is notcommercially available
